Note 4 - Revenue from Contracts with Customers |
3 Months Ended |
|---|---|
Mar. 31, 2026 | |
| Notes to Financial Statements | |
| Revenue from Contract with Customer [Text Block] |
Note 4 — Revenue from Contracts with Customers
Revenue Recognized
In the three months ended March 31, 2026 and 2025, the Company recognized revenue of $1,256 and $828, respectively, resulting from the delivery of patient EsoGuard test results. Revenue recognized from customer contracts deemed to include a variable consideration transaction price is limited to the unconstrained portion of the variable consideration.
Cost of Revenue
The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties.
In the three months ended March 31, 2026 and 2025, the cost of revenue was $1,625 and $1,551, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies.
|